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The growth rate of Cloudman 891 melanoma cells was 
compared in groups of normal and immunologically 
compromised DBA/2 mice that had undergone thymec-
tomy and treatment with antilymphocyte serum. Tumor 
growth was markedly accelerated in the immunosup-
pressed animals. Other groups of normal and immuno-
suppressed animals were treated with daily injections of 
either histamine, the H-2 antihistamine cimetidine, the 
H-1 antihistamine pyrilamine; or the mast cell stabilizer 
proxicromil. Histamine treatment accelerated tumor 
growth, but only in normal animals and had little effect 
on tumor growth in immunocompromised hosts. Cime-
tidine treatment tended to increase tumor growth in 
normal hosts but this was statistically significant in only 
1 of 3 experiments. In contrast, treatment with cimeti-
dine, pyrilamine, or proxicromil always resulted in sig-
nificant retardation of tumor growth in immunosup-
pressed animals . 
These data are consistent with the notion that thymec-
tomy and treatment with antilymphocyte serum results 
in enhanced tumor growth that is in part due to activa-
tion of histamine-dependent suppressor cells. In this 
system, histamine activation of suppressor cells may be 
reversed by treatment with either antihistamines or 
proxicromil, a drug th~t prevents mast cell release of 
histamine. However, since the effects of these drugs seem 
to depend on the immune status of the host, thorough 
evaluation of immunoregulatory function and careful 
testing to determine whether histamine blockers reduce 
or promote tumor growth would seem indicated when 
immunomodulatory treatment with these drugs is con-
templated. 
The immune response of an a nimal to antigens is the result 
of complex interactions between regulatory cells a nd effector 
cells [1]. The function of suppressor/cytotoxic T lymphocytes, 
and h elper / inducer T cells can be influenced by a variety of 
endogenous m ediators [2]. For example, T-cell function is influ-
enced by histamine in a variety of ways that can result in 
suppression or a ugmentation of responses [3-8). Thus, r elease 
of histamine from mast cells may be an important modulator of 
immune responses. 
Cimetidine, a histamine-2 receptor antagonist, seems to a ug-
ment T cell-mediated immunity in vivo and in vitro and has 
been reporteci to reverse anergy [9-15]. Treatment.of mice with 
cimetidine has been reported to retard the growth of several 
tumors. Its effects possibly are mediated by decreasing the 
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number and activity of suppressor T cells by blocking hista-
mine-2 receptors that are activated by histamine released dw--
ing immune responses [16,17]. In addition, tumors in human 
subjects who were receiving cimetidine have been observed to 
regress [18]. 
We ha ve shown previously that Cloudman m elanoma grow-
ing in syn geneic DBA/2 mice can activate either helper /inducer 
or suppressor T cells [19-21]. Tumor growth is retarded or 
enhanced depending on the predominating effect. In this tumor 
system, the dose of antigen seems critical for determining 
whether the helper / inducer or suppressor function predomi-
nates [20). We tested th e effect of in vivo treatment with 
cimetidine or histamine on th e growth of tumor cells in this 
system . We observed that histamine treatment accelerated 
tumor growth in normal mice and that cimetidine blocked 
tumor growth in immunosuppressed animals. Other histamine 
blockers like pyrilamine (a histamine H-1 blocker) and proxi-
cromil (a mast cell stabilizer that prevents histamine release) 
also retarded tumor growth in immunodeficient mice. 
MATERIALS AND METHODS 
Animals 
DBA/2 male mice, 6 weeks of age, were purchased fi:o m Jackson 
Laboratories, Bar Harbor, Maine, and for a ll experiments were main-
tained in groups of 6-8 per cage as described previously [19,20]. 
Tumors 
Cloudman S-91 melanoma was obtained from the American type 
tissue culture collection. It is syngeneic and grows well in DBA/ 2 mice. 
Melanoma cells for these experiments were obtained by excising 0.5 x 
0.5 em nodules from normal mice. The tumors were washed, gently 
passed through a screen, and filtered through gauze as reported previ-
ously [20,21]. Gentle centrifugation removed clumps. Viable cells (try-
pan blue) were counted in a hemocytometer. About 50% of the cells 
were viable in each preparation. Viable cells 1 x 10" were injected 
subcutaneously into the skin over the back which had been shaved 
previously to remove fur. 
Drugs 
Cimetidine was obtained from Smith, Kline, and French (Philadel-
phia, Pennsylvania) and was dissolved in sterile distilled water without 
preservatives. All drugs were injected i.p. The dose of cimetidine was 
5 mg/kg per day. The dose of histamine hydrochloride (Sigma, St. 
Louis, Missou1·i) was 50 mg/ kg per day; pyrilamine (Sigma) 10 mg/ kg 
per day; proxicromil (Fisons, Loughborough, England) 10 mg/ kg per 
day; and methysergide (Sandoz) 10 mg/ kg per day, all as described 
previously (22]. 
Immunosuppression 
Mice were immunosuppressed at 6 w'eeks of age by surgical removal 
of the thymus gland through the sternal notch as described previously 
(19,20]. Each mouse received an injection of antimouse lymphocyte 
serum (ALS, Microbiologic Associates, Bethesda, Maryland) 0.25 rn1 at 
24 and 96 h after the thymectomy. Mice treated by this regimen are 
significantly immunosuppressed and will accept allografts of B16 mel-
anoma tumors that are rejected by untreated controls [19]. Animals 
were injected with syngeneic Cloudman melanoma cells 10 days post 
surgery. 
Controls 
Control animals were injected with the diluents used for the drug-
treated animals. 
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Tumor Growth 
Tumor cells were inj ected s.c. under skin that had been shaved 
previously. The tumor was immediately visible fo Llowing inoculation. 
Tumor size was measUl"ed twice a week with a calipers and determined 
by summing the length of the longest ax is and its perpendicular. 
Statistical Methods 
The largest diameter (length) and width (perpendicular of the length) 
of the tumors were measured and added. The mean SD and SE were 
calculated for each group for each day of measurement. The growth 
rates were plotted and statistical differences for means, variances, and 
slopes among groups were analyzed by Student's t, Bartlett's chi-square, 
and slope analysis tests with a biomedical statistical computer program 
with the assistance of Mr. Emmanuel Lerner, statistician. 
RESULTS 
Immunosuppression Enhances Tumor Growth (Figs 1-4) 
Thymectomy and injections of ALS enh anced the growth of 
tumor cells compared to controls. Fig 1 shows that 17 days after 
injection of tumor cells the mean tumor size in the immunocom-
promised animals was significantly larger ( p < 0.01) than in the 
normal controls. The difference in the rate of growth persisted 
for the duration of the entire experiment. 
Cimetidine Treatment May Enhance Tumor Growth in Nor-
mal Mice (Figs 1, 2) 
Comparable groups of normal and thymectomized plus ALS-
treated mice were injected with tumor cells. Cimetidine therapy 
was initiated on the same day. In 2 experiments, cimetidine 
treatment seemed to accelerate the growth rate of the tumor in 
normal animals. However, in neither experiment was the growth 
rate in the cimetidine-treated animals statistically different (p 
< 0.05) from normal animals receiving diluent. The results of 1 
of these 2 similar experiments are shown in Fig 1. In a third 
experiment (Fig 2), cimetidine enhanced tumor growth at a 
statistically significant rate (p < 0.04). However, in this exper-
iment tumor growth was atypically slow. Tumors in normal 
animals were not visible for 42 days and accelerated growth was 
first confirmed after 45-50 days. 
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FIG 1. Growth rates of Cloudman melanoma in normal (N) and 
immunosuppressed {I) (thymectomized and ALS-treated) DBA/2 mice 
observed in 1 of2 identical experiments. Tumor growth was significantly 
faster 111 Immunosuppressed mice (N vs. I: p < 0.01 at • and all 
subsequent time points) . Cimetidine (5 mg/kg/day) was administered 
to groups of 6 normal (N+C) and immunosuppressed (l+C} mice. 
Cimetidine did not significantly enhance growth in normal animals< ~N 
vs. N+C: p > 0.05) but did significantly retard growth in immunosup-
pressed animals (I vs. I+C: p < 0.01 at + and all subsequent time 
points) to rates similar to those obse:rved in normal, immunologicaLly 
mtact mice that received cimetidine (i.e., N+C vs. l+C: p > 0.05 at all 
t ime points). 
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FIG 2. The growth rates of Cloudman melanoma in normal ( N) and 
immunosuppressed (!) DBA/ 2 mice observed in a third experiment. In 
th is experiment, tumor growth in a ll animals was slower than that 
observed in other experiments. Injections of cimetidine (5 mg/ kg/ day) 
significantly enhanced the growth of tumor in normal animals (N vs. 
N+C: p < 0.04 at+ and all subsequent time points). Thymectomy and 
ALS treatment accelerated tumor growth ( N vs. I: p < 0.01 at • and all 
subseq uent time points). Cimetidine retarded growth of the tumor in 
immunosuppressed animals {l+C) by day 45 (*) compared to that in 
immunosuppressed (!) mice but the difference reached statistical sig-
nificance (I vs. I+ C: p < 0.04) only at day 55 and all subsequent time 
points. 
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FIG 3. The effect of pyrilamine (Py) and proxicromil (Pr) on tumor 
growth in normal (N) and immunosuppressed {I) DBA/ 2 mice. Pyril-
amine (10 mg/kg/ day) and proxicromil (10 mg/ kg/day) had no effect 
on tumor growth in normal mice (data not shown;p > 0.10) . Pyrilamine 
and proxicromil both retarded growth in immunosuppressed animals 
(I vs. I+Py: p < 0.05 at x and all subsequent time points); (I vs. I+ Pr: 
p < 0.01 at+ and all subsequent time points) (N vs. I: p < 0.01 at • and 
aU subsequent time points). 
Cimetidine Treatment Retards Tumor Growth in Immunosup-
pressed Hosts (Figs 1, 2) 
In contrast to the possible enhancement of tumor growth in 
normal animals treated with cimetidine, similar treatment of 
thymectomized plus ALS-treated mice resulted in a significant 
delay m> tumor growth (p < 0.01) in all experiments (Figs 1, 2). 
It appeared that cimetidine treatment reversed the enhance-
ment of tumor growth that accompanied thymectomy plus ALS 
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FIG 4. The effect of histamine (H) on growth rates of Cloudman 
melanoma in normal (N) and immunosuppressed (!) DBA/2 mice. 
Histamine (50 mg/ kg/ day) minimally delayed tumor growth in immu-
nosuppressed mice (I vs. l+H: p ,;;; 0.05 at x and all subsequent time 
points). Histamine accelerated the growth of tumors in normal animals 
(N vs. N+H: p < 0.05 at+ and all subsequent time points). 
treatment. In fact, tumor growth in the immunosuppressed 
animals that were injected with the cimetidine was not different 
from the growth of the melanoma in the normal immunologi-
cally intact animals that received cimetidine. 
Treatment with Pyrilamine or Proxicromil Also Reverses Tu-
mor Enhancement in Immunocompromised Mice (Fig 3) 
In another experiment, groups of thymectomized plus ALS-
treated mice or normal mice were injected with tumor cells and 
were treated with diluent -or with pyrilamine (a histamine-! 
receptor antagonist) or proxicromil (a mast cell stabilizer that 
prevents degranulation and release of mediators such as hista-
mine from mast cells). In normal animals, the drugs had no 
effect on the rate of tumor growth (data not shown) . In thy-
mectomized plus ALS-treated animals, treatment with pyril-
amine (p < 0.05) or proxicromil (p < 0.01) significantly delayed 
the growth of the tumor. Thus, treatment with cimetidine, 
pyrilamine, and proxicromil, drugs that either block the effects 
of histamine or prevent histamine release, had little effect on 
the growth of tumor cells in normal animals, but uniformly 
reversed the enhancement of tumor growth observed in im-
munosuppressed hosts. 
Treatment with Histamine Accelerates Tumor Growth in Nor-
mal Mice (Fig 4) 
Histamine 10 mg/ kg was injected daily into mice bearing 
tumors. In _thymectomized plus ALS treated mice, there was a 
slight tendency for histamine to delay tumor growth (p::; 0.05) . 
However, in normal mice the tumor was rapidly accelerated at 
a statistically significant rate from day 20 to the end of the 
experiment at day ~8 (p < 0.05). Thus, in contrast to treatment 
with antihistamines or a drug that blocks htstamine release, all 
of which reversed the tumor-enhancing effect of thymectomy 
and ALS, treatment with histamine accelerated tumors, but 
only in normal animals. 
Treatment with M ethysergide Has No Effect on Tumor Growth 
Methysergide is a serotonin antagonist. Although the mast 
cells of mice contain and release both histamine and serotonin, 
the vasculature of mice is far more sensitive to serotonin than 
to histamine [23]. Treatment of mice with methysergide at 
doses that block the vasoactive effects of serotonin leads to 
significant inhibition of the elicitation of delayed-type hyper-
sensitivity [22]. Treatment of tumor-inoculated mice with this 
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methysergide regimen had no effect on tumor growth in normal 
or immunosuppressed hosts (data not shown) . 
DISCUSSION 
Previous studies have reported that treatment with cimeti-
dine results in delayed growth of tumors in several rodent 
models [16,17]. These studies suggested that cimetidine, by 
blocking the ability of histamine to activate histamine-2 recep-
tors on suppressor T cells, might cause decreased suppression. 
In the system employed in this study we have shown previously 
that the functional activity of suppressor and helper T lympho-
cytes in DBA/2 mice depends upon the dose of melanoma 
tumor antigen to which they are exposed [20,21]. Animals that 
are thymectomized and receive ALS have activation of sup-
pressor cells and enhanced tumor growth [20,21]. Results of the 
cw-rent experiments suggest that histamine and/or histamine 
receptors are involved in the regulation of tumor immunity in 
this system. However, until precise assay of histamine modu-
lation of cellular immune resistance to tumor growth is avail-
able, the exact mechanism of the effects we have seen will 
remain speculative. 
We found that treatment with histamine enhanced tumor 
growth in normal animals. This could be due to the ability of 
histamine to activate suppressor cells [5,8,24] or inhibit effector 
T cells [3,4,6]. In contrast, treatment with antihistamines 
(either pyrilamine an H-1 antagonist, or cimetidine an H-2 
antagonist), or treatment with a drug that stabilizes mast cells 
and prevent histamine release (proxicromil), all resulted in a 
retardation of tumor growth in immunodeficient mice. The 
mechanism of this antitumor effect may involve blocking sup-
pressor cell activity. Whether the effects of the antihistamines 
were due to blockade of histamine receptors is not known. 
These drugs can have effects on the function of immune cells in 
the absence of histamine [25]. The effect of proxicromil suggests 
that tissue mast cells may be involved in the growth. of tumor. 
Proxicromil may act by blocking mast cell degranulation and 
release of histamine [26] which then activates suppressor cells. 
Mast cells may also be involved in promoting tumor growth in 
this system through release of heparin which is known to be a 
potent angiogenesis factor that may promote the growth of 
vessels that support tumor growth (27]. 
Our results suggest that the effects of cimetidine treatment 
may be more complex in tumor immunity than realized previ-
ously. Other workers have demonstrated an antitumor effect of 
cimetidine treatment and postulated that this was due to an 
interference with suppressor cell function [16,17]. Our findings 
are consistent with this formulation. Cimetidine treatment re-
versed accelerated tumor growth in immunocompromised hosts 
known to have augmented suppressor cell activation as the 
basis for tumor enhancement [20,21]. In contrast, cimetidine 
treatment had no effect on tumor growth in normal hosts in 2 
experiments, and actually enhanced tumor growth significantly 
in 1 experiment. The atypically slow growth of tumor in this 
experiment may reflect a delay in suppressor cell activation, 
perhaps due to an effectively low dose of tumor. The fact that 
the effects of the drugs depended on the immune status of the 
host makes it unlikely that the drugs had a direct effect on the 
growth of tumor cells [16,17]. It is noteworthy that Osband et 
al demonstrated an antitumor effect in mice when cimetidine 
treatment was begun 7-9 days after tumor inoculation at a time 
when there was a significant increase in histamine reactive 
suppressor cells [16]. Thus the effect of cimetidine appears to 
depend on the immune status of the host. Therefore great 
caution needs to be exercised in selecting tumors for treatment 
with cimetidine since an antitumor effect may occw- in immu-
nosuppressed individuals, but tumor enhancement could occur 
when there is a normal immune response. 
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The Thymus Dependency of Acquired Resistance to Trichophyton 
mentagrophytes Dermatophytosis in Rats 
FREDERICK GREEN, III, PH.D., JOANNE K. WEBER, B .S., AND EDWARD BALISH, PH.D. 
Departments of Surgery and Medical Microbiology, University of Wisconsin Medical School, Madison, Wisconsin, U.S.A . 
Congenitally a thymic "nude" (RNU / RNU) rats and 
euthymic ( + /RNU) rats were cutaneously inoculated 
with Trichophyton mentagrophytes. Dermatophytosis, as 
evidenced by erythema and scaling, was observed in 
both athymic and euthymic rats by day 7 postinfection. 
Macroscopic lesions in + /RNU rats became intensely 
erythematous (climax days 10-14), were limited in 
spread and alopecia (days 16- 20), and healed with hair 
regrowth by day 35. In nude rats, however, erythema 
peaked early (days 8 - 10) and a persistent, mild erythema 
and scaling spread over the animals' backs. Viable T. 
mentagrophytes was cultured from the skin of all infected 
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uary 26, 1983. 
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nude rats for the duration of each experiment (90 days), 
while + /RNU rats became culture-negative by day 35. 
Following clearance of primary lesions, + / RNU rats 
manifest a delayed-type hypersensitivity skin test r e -
sponse to soluble trichophytin and an accelerated cuta-
neous inflammation and enhanced resistance t o r einfec-
tion. Although T. mentagrophytes primarily invaded the 
keratinized layers of the epidermis in both nude and + 1 
RNU rats, hyphae and arthrospores were also observed 
within the nucleated layers of the internal root sheath of 
hair follicles. 
Our observations are consistent with the hypothesis 
Abbreviations: 
CBH: cutaneous basophil hypersensitivity 
CMI: cell-mediated immunity 
DTH: delayed-type hypersensitivity 
ERS: external root sheath 
IRS: internal root sheath 
PAS: periodic acid-Schiff 
PMN: polymorphonuclear neutrophil 
